Observational study for the efficacy of add-on non-pharmaceutical interventions and of Viscum album extract for the treatment of patients with lung carcinoma
Recruiting
- Conditions
- C34Malignant neoplasm of bronchus and lung
- Registration Number
- DRKS00017083
- Lead Sponsor
- Forschungsinstitut Havelhöhe (FIH) gGmbH am Gemeinschaftskrankenhaus Havelhöhe
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Written informed consent, patients with primary lung carcinoma (stage UICC IIA - IVB - 8th edition), knowledge of Geman language, can expected to undergo a 3-months program (ECOG 0-2), inclusion within 4 weeks of primary diagnosis, if necessary plus 3 months depending on therapy
Exclusion Criteria
Primary lung carcinoma UICC I (8th edition), no written consent
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method QoL (Quality of life): FACT-TOI questionnaire, at the time points 0, 3, 6 und 12 , 24 und 36 weeks
- Secondary Outcome Measures
Name Time Method Safety, adverse events, Tumor Response Rate, QoL (Quality of Life) with the questionnaires FACT-L, FACT-TOI, CFS-D, PSQI, HADS, IPQR, F-Sozu, FEAV, PAF, State aR, Grossarth-Maticek's self-regulation and distress barometer, in addition overall survival and progression free survival; time points 0, 3, 6 und 12 , 24 und 36 weeks